GSK and Pfizer to create together a HIV-focused company
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Pfizer are to create together a new £250 million company specifically for developing novel HIV drugs and formulations to improve adherence and overcome resistance.